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ABSTRACT  
Introduction:Short-form versions of the Montreal Cognitive Assessment (SF-
MoCA) are increasingly used to screen for dementia in research and practice. We 
sought to collate evidence on the accuracy of SF-MoCAs and to externally 
validate these assessment tools.  
Methods:We performed systematic literature searching across multidisciplinary 
electronic literature databases, collating information on the content and accuracy 
of all published SF-MoCAs. We then validated all the SF-MoCAs against clinical 
diagnosis using independent stroke (n=787) and memory clinic (n=410) data-
sets.  
 
Results:We identified 13 different SF-MoCAs (21 studies, n=6477 participants) 
with differing test content and properties. There was a pattern of high sensitivity 
across the range of SF-MoCA tests. In the published literature, for detection of 
post-stroke cognitive impairment, median sensitivity across included 
studies:0.88 (range:0.70-1.00); specificity:0.70 (0.39-0.92). In our independent 
validation using stroke data, median sensitivity:0.99 (0.80-1.00); 
specificity:0.40 (0.14-0.87). To detect dementia in older adults, median 
sensitivity:0.88 (0.62-0.98), median specificity:0.87 (0.07-0.98) in the literature 
and median sensitivity:0.96 (range:0.72-1.00); median specificity:0.36 (0.14-
0.86) in our validation. Horton’s SF-MoCA (delayed recall, serial subtraction, 
orientation) had the most favorable properties in stroke (sensitivity:0.90, 
specificity:0.87, PPV:0.55, NPV:0.93), whereas Cecato’s ‘MoCA reduced’ (clock 
draw, animal naming, delayed recall, orientation) performed better in the 
memory clinic (sensitivity:0.72, specificity:0.86, PPV:0.55, NPV:0.93).  
Conclusions:There are many published SF-MoCAs. Clinicians and researchers 
using a SF-MoCA should be explicit about the content. For all SF-MoCA, 
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sensitivity is high and similar to the full scale suggesting potential utility as an 
initial cognitive screening tool. However, choice of SF-MoCA should be informed 
by the clinical population to be studied. 
 
Key words: Dementia, Cognitive Impairment, Montreal Cognitive assessment, 
sensitivity, specificity 
 
 
Key Points: 
• Many scales purport to be a short form of the MoCA (SF-MoCA). 
• SF-MoCAs are not interchangeable; the scales differ in content, scoring 
and accuracy.  
• SF-MoCAs generally have high sensitivity and lower specificity.  
• Properties of SF-MoCAs make them suitable as an initial cognitive 
screening test, where a ‘positive’ result is followed by more detailed 
assessment (sometimes called a ‘rule out’ test).  
• Optimal content of SF-MoCAs used in stroke may differ from that used in 
other settings. 
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Introduction  
There is no consensus on how to approach screening older adults for cognitive 
impairment or dementia.1 In non-specialist settings, the assessment of cognition 
often takes a two-stage approach, with initial screening or triage using a short 
test followed, where necessary, with more detailed testing.  The Montreal 
Cognitive Assessment (MoCA) has gained traction as a short cognitive screening 
tool.2  Although initially developed as a screen for mild cognitive impairment 
(MCI), the MoCA is now often used as a general cognitive screen and as a 
dementia assessment.3 
 
Completion of the MoCA in the literature is generally quoted as around 10 
minutes,4 but in practice it can be much longer if the patient is medically unwell 
or has physical or cognitive impairments, a situation that is common in clinical 
practice.5  While the MoCA is short compared to a comprehensive 
neuropsychological battery, it may still be too long for use as an initial screen in 
busy medical units.  A shorter screen retaining diagnostic properties of the MoCA 
is attractive for both patients and clinicians. It could enable cognitive screening 
to be routinely integrated into greater clinical settings and reduce the 
assessment burden on patients.   
 
Many multi-item assessments have some redundancy and certain component 
items can be removed to create a shorter version of the original.  Short form 
versions of quality of life and activities of daily living assessments are commonly 
used in practice and research.6,7  Short form versions of the MoCA (SF-MoCA) 
have also been described.  While use of a SF-MoCA is intuitively attractive, 
validity of such an assessment should not be assumed.  Even if the process of 
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developing the SF-MoCA is robust and the accuracy metrics favorable, it is still 
necessary to externally validate the new test in an independent data-set.  
 
We used a two-stage process to describe the test properties of the SF-MoCA.  
First, we collated and reviewed the content and diagnostic accuracy of all 
published SF-MoCAs and then we externally validated these scales using 
independent data-sets.  
 
Methods 
Systematic review  
We carried out a systematic review of the literature looking to describe the 
content and diagnostic properties of any short-form versions of the MoCA.  We 
followed best practice in all aspects of design, conduct and reporting.8,9  All 
searching, data extraction and quality assessment were performed by 
independent researchers (JM, GB, EE) with access to a third arbitrator (TQ) as 
needed.  Our protocol is registered with the research registry database 
(http://www.researchregistry.com. UIN: reviewregistry298). 
 
Search strategy: We developed search terms using a concept-based approach.  
The first concept of interest was MoCA and its synonyms, including names of 
existing short-forms known to the researchers. The second concept was around 
short-form tests/item reduction.  The vocabulary used for the second concept 
had been validated in a previous systematic review of short-form tests.7  We 
searched a series of multidisciplinary electronic databases from 2005 (year of 
publication of original MoCA paper) to April 2017: MEDLINE (OVID), Embase 
(OVID), Health and Psychosocial Instruments (OVID), PsychINFO (EBSCO), 
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CINAHL (EBSCO). We included all studies in all languages, translating where 
necessary.  We included published abstracts in initial data synthesis but these 
data sources were not assessed for reporting or risk of bias. 
 
We screened all titles generated by initial searches for relevance.  Abstracts 
were assessed and potentially eligible studies were reviewed as full manuscripts 
against inclusion criteria. We searched reference lists of included studies and 
relevant reviews, repeating the process until no new titles were found (Full 
search strategy available in Supplementary Methods 1).  
 
Systematic review inclusion and exclusion criteria: Our index test of 
interest was any SF-MoCA.  We defined the SF-MoCA as a test of more than one 
cognitive domain, derived from the original MoCA and designed to detect all-
cause dementia or cognitive impairment.  We did not include the ‘MoCA-Basic’, 
which is a MoCA designed for patients with limited education rather than a 
shortened form.10  Included studies used a test accuracy design, where SF-MoCA 
was compared to a gold-standard clinical diagnosis of dementia, or cognitive 
impairment.  We included studies where the comparator was the full MoCA or 
another multi-domain assessment.  We included studies in any setting 
(community, primary, secondary care) and for any intended use of the test 
(research, screening, assessment). 
 
Systematic review data extraction and assessments: We extracted data to 
a study specific proforma and created tables describing characteristics of 
included studies and characteristics of the index tests including the cognitive 
domains tested.  Where possible, we created 2x2 contingency tables to allow us 
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to derive metrics of sensitivity, specificity and predictive values 11. We contacted 
authors to obtain data or clarify methods, where needed. 
 
We assessed methodological quality and risk of bias using the Quality 
Assessment for Diagnostic Test Accuracy Studies (QUADAS-2) tool 
(www.bris.ac.uk/quadas/quadas-2).12 QUADAS-2 assesses four key domains; 
patient selection, application of index test, application of reference standard and 
patient flow/timing.  We assessed quality of reporting using the dementia-
specific extension to the Standards for Reporting of Diagnostic Accuracy 
(STARDdem) tool.13  
 
External validation of SF-MoCA 
We examined the properties of the MoCA and the different SF-MoCAs identified 
through systematic review by using independent data-sets that contained 
individual patient level data on MoCA (with scoring available for each individual 
component) and a reference standard comparator. We restricted our analyses to 
those SF-MoCAs designed to detect dementia. Our index tests were each 
differing SF-MoCA version found from our literature search. The SF-MoCA were 
derived from the full version of the test.  To align with our systematic review, 
our reference standard was clinical diagnosis of dementia or scores on a 
validated multi-domain cognitive assessment.  
 
Data-sets used for validation: As MoCA and SF-MoCA are often used in stroke 
settings, our first data-set had a stroke focus.14 The data-set was derived from 
the Virtual International Stroke Trial Archive (VISTA), a not-for-profit repository 
of anonymised data from stroke trials or observational cohorts.15 We included 
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any data-set that contained MoCA assessment and an appropriate reference 
standard.  Recognizing the difficulty of applying a dementia label in an acute 
stroke setting, and to align with our literature review, we included data-sets 
where comparator was diagnosis of dementia and datasets where comparator 
was a multi-domain cognitive assessment other than MoCA. For this stroke 
cohort, impairment in memory was not mandatory to assign the clinical label. 
Our second data-set was taken from a memory clinic setting (the Walton Centre, 
Liverpool UK). The data-set has been described in detail previously.16,17  In brief, 
MoCA is administered in clinic and then a clinical diagnosis was made by an 
independent clinician, masked to the MoCA score.   
 
Validation analyses: We described the internal consistency (reliability) of the 
MoCA in each data-set using Cronbach’s alpha. To identify potentially redundant 
items in the MoCA, we used spearman coefficient to describe the correlation 
between individual test items and total MoCA score and then described the effect 
on internal consistency if that item was removed. If internal consistency of the 
complete scale is unchanged when an item is removed, it suggests that the item 
is not contributing independent of other items and could potentially be removed 
without compromising test performance. We described rank correlation of each 
MoCA item with another. We used exploratory factor analysis and principle 
component analysis to assess the underlying structure of the MoCA i.e. how 
many differing constructs were being assessed by the scale. We assessed factor 
pattern and described factors that were positively loaded using standardized 
regression coefficients, where high loading was defined as >0.7.  
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We then described the test accuracy of the various SF-MoCAs. We described 
correlation of each SF-MoCA with the original MoCA.  We derived sensitivity, 
specificity and negative/positive predictive values (NPV/PPV) for each SF-MoCA 
(using recommended threshold scores from the literature) against clinical 
reference standard. All analyses used SAS version 9.4 (SAS Institute, Cary) 
software.   
 
This work was supported by a research grant from the British Geriatric Society. 
The funder had no role in managing data, performing analyses, interpreting data 
or drafting the manuscript. 
 
Results 
Systematic review: After de-duplication, we screened 578 titles, reviewed 140 
full papers and included 21 studies (18 full papers17-34 and three conference 
abstracts 35-37) (Figure 1). Numbers of participants included in studies ranged 
from n=59 to n=1850 (n=6477 participants in total).  Included studies assessed 
diverse patient groups, with a majority having a cardio/cerebrovascular focus 
(n=9 studies; Table 2 and Supplementary Table 1).   
 
There were 13 different published short versions of the MoCA with differing test 
items (range:2-8 items; total score 8-22); differing cut-offs to define ‘test 
positive’ and presented under different names (Table 1).  The most frequently 
described SF-MoCA was the 5-minute protocol recommended by the National 
Institute of Neurological Disorders and Stroke and the Canadian Stroke Network 
(NINDS-CSN) (n=7 papers). 
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Content of each SF-MoCA differed.  All SF-MoCAs retained the delayed recall 
item; the orientation and fluency items were also prevalent.  Digit span was the 
item most likely to be omitted from a short form (Table 1).   
 
Scoring in the short-forms was not always consistent with the original MoCA.  
For example, in one SF-MoCA version 24 immediate recall was scored; an item 
that is not scored in the original MoCA.  In other SF-MoCAs, animal naming used 
one animal instead of three17,27.  Cut-off scores employed to categorize patients 
varied across papers even where the same short-form was used (Table 1, Table 
2). 
 
The reported accuracy of the short-forms varied across the papers (Table 2 and 
Supplementary Table 1).  In papers with a stroke focus, median sensitivity was 
0.88 (range:0.70-1.00) and median specificity was 0.70 (range:0.39-0.92).   
Settings and timing of assessment using the index test (SF-MoCA) post-stroke 
varied: the majority of papers administered the tests >3 months’ post-stroke, 
one paper used the SF-MoCA in the acute period following stroke (≤2 weeks),31 
and two papers in the setting of a stroke prevention clinic (therefore some non-
stroke patients were also included)22,37(Table 2). 
 
In those papers where SF-MoCA was used to diagnosis dementia or MCI in older 
adults, median sensitivity was 0.85 (range:0.44-0.98), specificity was 0.74 
(range:0.07-0.98). Restricting to dementia diagnosis only, median 
sensitivity:0.88 (range:0.62-0.98), median specificity:0.87 (range:0.07-0.98). 
We did not attempt meta-analyses to create summary estimates of SF-MoCA 
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test accuracy due to the significant heterogeneity in test content, thresholds and 
populations.  
 
Using QUADAS-2, one study was considered to have a low risk of bias in all four 
areas.17  Potential for bias in the other studies was generally around patient 
selection (n=17) (inappropriate exclusions, non-consecutive samples), use of 
index test (n=11) (no pre-specified cut-off) and the timing between the index 
test and reference standard not reported or ambiguous (n=9) (Supplementary 
Table 2). Eight papers were of particular concern (rated high or unclear risk of 
bas across three areas).21,25-27,29,31,34,38 Study reporting was variable and no 
study reported all items recommended in STARDdem guidance. (Supplementary 
Table 3) 
 
External validation of SF-MoCA: Our stroke analyses used data from 787 
stroke patients with a median age of 70, median NIHSS of 4, median MoCA of 21 
and 289 (37%) had dementia or post-stroke cognitive impairment.  Assessments 
were performed in the acute period (first weeks) following stroke.  Our memory 
clinic analyses used data from 410 patients, with median age of 60, median 
MoCA of 23 and 79 (19%) had dementia.  
From 13 differing versions of SF-MoCA, we performed validation analyses on 11 
tests. We excluded one SF-MoCA as it was designed to detect MCI rather than 
dementia.25 We excluded one other SF-MoCA as it included additional content 
(immediate recall)24 that is not part of the original MoCA scoring and we 
therefore could not retrospectively score it.  
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Internal consistency for the full MoCA was 0.88 for the stroke data-set and 0.82 
for the memory clinic.  In the stroke data-set clock drawing was the single item 
most correlated with total score, while sentence repetition was least correlated.  
In the memory clinic data-set, orientation questions were most correlated and a 
letter based attentional task least.  In both data-sets item reduction did not 
suggest a redundant item (Supplementary Table 4). In both data-sets, 
correlation of one item with another did not suggest a redundant item (no 
correlation >0.6; Table 3).  Exploratory factor analyses and principal 
components analysis suggested a unidimensional scale, with only clock drawing 
highly loaded (0.76) in the stroke data-set and no items highly loaded in the 
memory clinic data (Supplementary Table 5). 
 
The test accuracy of the published SF-MoCAs varied when assessed in our 
independent data-sets. Test accuracy of the full MoCA was included for 
comparison at the usual threshold of <26. Accuracy was similar in the two data-
sets; sensitivity:1.00 in both, specificity:0.22 in stroke, 0.26 in the memory 
clinic data-set. In both data-sets, the SF-MoCA versions were highly correlated 
with the full MoCA (all >0.80).  For the stroke trial data-set, median sensitivity 
was:0.99 (range:0.80-1.00); median specificity:0.40 (range:0.14-0.87), 
PPV:0.48 (range:0.40-0.82), NPV:0.99 (range:0.88-1.00). The SF-MoCA with 
the most favorable balance of test properties (sensitivity, specificity, PPV, NPV) 
in stroke was Horton’s SF-MoCA (comprising: delayed recall, serial subtraction, 
orientation).   
 
For the memory clinic data-set, median sensitivity:0.96 (range:0.72-1.00); 
median specificity:0.36 (range:0.14-0.86), PPV:0.27 (range:0.24-0.55), 
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NPV:0.97 (range:0.93-1.00) (Figure 2). Cecato’s ‘MoCA reduced’25 (comprising: 
clock draw, single animal naming, delayed recall, orientation) showed best 
performance in the memory clinic population.  
 
Discussion 
Our systematic review found many cognitive tests that purport to be a shorter 
form of the MoCA.  The available SF-MoCA are not interchangeable as they have 
differing test items, application and test properties.  Our external validation of 
the SF-MoCA confirmed differences in test properties.  Accepting this 
heterogeneity, in general the SF-MoCA had a pattern of high sensitivity and 
lower specificity, with corresponding high negative predictive value and lower 
positive predictive value. 
 
Various approaches to developing short versions of longer tests are described 39. 
The processes used to develop the various published SF-MoCA varied.  In terms 
of psychometrics, it is debatable whether the MoCA content should be reduced at 
all.  Our analyses suggest no obviously redundant item in the original MoCA.  
Indeed, our factor and components analyses would not necessarily favor the 
creation of a shorter form. In spite of whether it is considered ‘correct’ to 
shorten tests, certain scenarios, such as test administration by telephone23 
necessitate that certain items from the original scale are discarded, effectively 
creating a short form assessment.  We note that the team who developed the 
original MoCA are working on a shortened, 5-minute version. Although this 
official short MoCA is not released at the time of writing, the developers state 
that the tool will predominantly assess memory and executive functions.  
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The terminology used to describe the short versions of the MoCA is potentially 
confusing.  Some of the short-form tests were presented under the same name, 
yet contained different items, for example there were two versions of the “mini-
MoCA”22,37 and two of the “MoCA reduced”.25  Conversely, some SF-MoCA had 
identical content and scoring but had a different title, for example the “new short 
MoCA” and “mini-MoCA” were the same test.18,20 Abbreviations also potentially 
add to the confusion with ‘MoCA-B’ being used to describe both the ‘MoCA Basic’ 
and ‘MoCA Blind’ tests.10,28 We would encourage researchers and clinicians to be 
explicit about the test content and scoring when using a SF-MoCA.   
 
The SF-MoCA was used in a variety of patient populations.  Many of the 
populations assessed represented neurodegenerative diseases where patients 
are likely to have mixed physical and cognitive impairments (multiple sclerosis, 
Parkinson’s disease, stroke).  In these settings a short cognitive test may have 
particular utility as patients may struggle to complete a longer test battery.5 
More specifically the choice of SF-MoCA could be tailored, for example removing 
questions requiring drawing for patients with limb weakness.  The MoCA test 
items that were most discriminating differed between stroke and memory clinic 
patients.  This finding has biological plausibility as the predominant dementia 
pathologies will also differ in these patient groups, with greater impairment of 
executive function in the stroke group.14 This suggests that the optimal short 
form may depend on the population to be tested. The NINDS-CSN recommended 
a 5-minute protocol specifically for VCI, however this was also the choice of test 
in those papers that studied test performance in non-vascular groups e.g. MS 
and PD populations.   
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Across the different SF-MoCA, a general pattern emerges of high sensitivity and 
lower specificity with corresponding high NPV and lower PPV.  These results are 
not surprising since the MoCA was designed to detect milder cognitive 
impairment and we focused on dementia. There is no ‘acceptable’ value for test 
accuracy and the preferred trade off of NPV and PPV will vary with the purpose 
of the test.11 The test accuracy findings for SF-MoCA suggest that the test is 
useful for ‘rule-out’ i.e. a negative or normal SF-MoCA makes it unlikely that a 
person has important cognitive issues. With specificity being low across many of 
the SF-MoCAs, a positive or abnormal SF-MoCA is less helpful (many false 
positives) and will need to be followed by further assessment. In this regard the 
properties of SF-MoCA are similar to the original MoCA, where sensitivity for a 
dementia diagnosis is around 94% and specificity less than 60%.3  
 
There are limitations in our work.  For our systematic review we were 
constrained by the methodology and reporting of the original research.  Many of 
the original papers had substantial risk of bias.  We adopted an inclusive 
approach and accepted papers where SF-MoCA was compared only to the 
original MoCA.  This is a less useful analysis than comparison against a clinical 
diagnosis, since the MoCA itself is an imperfect cognitive assessment.  In our 
external validation we derived SF-MoCA data from the original MoCA test data.  
We recognize that the properties of a SF-MoCA may differ if used directly rather 
than if retrospectively derived.  We also used a mixed reference standard of 
clinical diagnosis and multi-domain assessment.  We felt that this approach was 
representative of real-world practice where a diagnosis of post stroke dementia 
may not be made in the acute period. We also acknowledge that using a 
neurology-led memory clinic population for validation has some limitations.  
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These patients are likely to be selected and may have already been triaged using 
a cognitive screen, and brief tests are less useful in this specialist setting. These 
factors all potentially limit the generalisability of our findings.  The different 
accuracy found in our validation analyses compared to studies included in our 
review are likely due to methodological limitations, differing case-mix and 
differing comparator groups.  Finally, due to our validation being a secondary 
analysis, we were unable to adjust our results for education, which would usually 
be done in practice. Strengths of our approach include the use of a 
comprehensive search strategy and validated assessments of reporting and bias.  
By externally validating the tests in a large sample we were able to test their 
performance in a real-world setting.   
 
Our findings have implications for research and practice.  The test properties of 
certain SF-MoCA and the original scale are comparable and so in some situations 
the SF-MoCA may be preferred to the full MoCA for initial screening.  The choice 
of SF-MoCA should also be informed by other test properties such as feasibility 
and reduced test burden.  Although this is the obvious advantage to a short 
form, few studies have reported metrics such as time taken for assessment or 
percentage test completion.  Further research that describes these properties 
would help guide choice of SF-MoCA.  As the short versions have a theoretical 
advantage of greater feasibility, in any future research the test population 
should be an unselected cohort that includes participants with physical, language 
and sensory impairments that may complicate cognitive assessment.  
 
Conclusion 
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The cognitive tests named ‘mini-MoCA’; ‘short-form MoCA’; ‘5 minute-MoCA’ etc. 
describe a variety of differing cognitive assessments with differing content and 
test properties.  The psychometric properties of the MoCA do not suggest 
preferred content of a shorter version and so choice of SF-MoCA should be based 
on accuracy and feasibility.  Test accuracy of the various published SF-MoCA 
suggests that these tests may be best used as initial cognitive screening tests, if 
the purpose of testing is to rule out dementia. However, such an approach 
should be prospectively validated in an independent sample before being used in 
a clinical setting.  
 
Data Availability 
The data that inform the analyses included in this paper are available from the 
authors upon reasonable request. 
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Table 1. Content and scoring of published, named short-form versions of 
Montreal Cognitive Assessment  
 
 
Name of short-
form MoCA 
Number of 
test items 
Description of test items 
included and scoring 
Cut offs suggested by 
each paper 
Abbreviated MoCA 2 Clock draw (3) 
Delayed recall (5) 
/8 
Panenkova 2016: <4 
NINDS-CSN 5 min 
protocol 
*T-MoCA short 
3 Delayed recall (5) 
Fluency (1) 
Orientation (6) 
/12 
Bocti 2013a: <10 
Cameron 2016: <10 
Dong 2015 (PD): <13 
Kaur 2013: <11 
Lim 2017: <7 
Lin 2016: Not stated 
*Pendlebury 2013: <10 
Xu 2016: Not stated 
Mini-MoCA 3 Clock draw (3) 
Delayed recall (5) 
Abstraction (2) 
/10 
Mai 2013: <7 
Davies 2011: Not stated 
SF MoCA 3 Delayed recall (5) 
Serial 7 (3) 
Orientation (6) 
/14 
Horton 2015: <9 
MoCA 5 min 
protocol 
4 Immediate recall (5) 
Delayed recall (10)* 
Fluency (9)** 
Orientation (6) 
/30 
* 2 points for each word free 
recall. 1 point for cued 
recall/recognition 
** Animal fluency. 0.5 point for 
each word 
Wong 2015: <15 
MoCA reduced 4 Clock draw (3) 
Animals (rhino) (1) 
Delayed recall (5) 
Cecato 2016 (AD): <9 
 23 
Orientation (6) 
/15 
Four item mini-
MoCA 
4 Cube copy (1) 
Delayed recall (5) 
Serial 7 (3) 
Fluency (1) 
/10 (paper states total is 11) 
Bocti 2012: <9 
New short MoCA 
*Mini-MoCA 
5 Trails (1) 
Cube copy (1) 
Delayed recall (5) 
Fluency (1) 
Abstraction (2) 
/10 
Bocti 2013b: <7 
Campbell 2016: <7 
5 min MoCA 5 Clock draw (3) 
Delayed recall (5) 
Serial 7 (3) 
Fluency (1) 
Orientation (6) 
/18 
Dong 2015 (stroke): <13 
EM-MoCA 7 Trails (1) 
Cube copy (1) 
Clock draw (3) 
Delayed recall (5) 
Fluency (1) 
Abstraction (2) 
Orientation (6) 
/19 
Freitas 2018: <17 
MoCA reduced 7 Animals (rhino) (1) 
Delayed recall (5) 
List letters (1) 
Sentence repetition (2) 
Fluency (1) 
Abstraction (2) 
Orientation (6) 
/18 
Cecato 2016 (MCI): <14 
 24 
S-MoCA 8 Trails (1) 
Clock Draw (3) 
Animals (rhino) (1) 
Delayed recall (5) 
Serial 7 (3) 
Fluency (1) 
Abstraction (measurement) (1) 
Orientation (place) (1) 
/16 
Larner 2017: <12 
Roalf 2017: <12 
T-MoCA 
*MoCA-Blind 
8 Delayed recall (5) 
Digit span (2) 
List letters (1) 
Serial 7 (3) 
Sentence repetition (2) 
Fluency (1) 
Abstraction (2) 
Orientation (6) 
/22 
Pendlebury 2013: <18 
*Wittich 2010: <19 
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Table 2. Characteristics of stroke and older adults’ studies included in 
systematic review 
Study ID Subjects (n) 
Target 
Conditi
on 
Index Test 
Setting/timi
ng of index 
test post-
stroke  
Referenc
e 
Standard 
Cut-off Sensitivity In study 
Specificity 
In Study  
Stroke 
Bocti 2013 386 CI  
New Short 
MoCA 
3 months  
MoCA 
<7/10 91% 83% 
NINDS-CSN 
5 min 
protocol 
 
<10/12 87% 74% 
Campbell 
2016 72 CI  Mini-MoCA 
Rehab unit Cognistat <7/10 93% 92% 
Davies 
2011 (CA) 102 CI  Mini-MoCA 
Stroke 
prevention 
clinic 
MoCA not reported not reported 
not 
reported 
Dong 
2015 (CA) 327 CI  5 min MoCA 
3-6 months NPB <13/20 70% 87% 
Lim 2017 308 Dementia  
NINDS-CSN 
5 min 
protocol 
≤2 weeks 
NPB <7/12 82% 67% 
Lin 2016 83 CI  
NINDS-CSN 
5 min 
protocol 
3-18 months MDT 
Consensus <15/30 81% 55% 
Mai 2013 102 CI  Mini-MoCA 
Stroke 
prevention 
clinic 
MoCA <7/10 99% 78% 
Pendlebur
y 2013 
 
68  
Multi-
domain 
MCI  
T-MoCA >1 year post stroke  
NPB 
<18/22 100% 52% 
T-MoCA 
Short 
(NINDS-
CSN) <10/12 83% 48% 
Wong 
2015 104 CI  
MoCA 5 min 
protocol 
39 days  CDR (0.5 
or 1) <15/30 84%
a   73%a 
Older Adults  
Horton 
2015 
Derivatio
n Group 
=317 AD vs 
MCI+H
C 
SF-MoCA MDT Consensus  
Unknow
n 95%
b 87%b 
Validatio
n Group 
= 91 
unknow
n 80%
b 95%b 
Cecato 
2016 97 
AD vs 
MCI Reduced MoCA DSM IV <8.5/18 85% 87% 
Larner 
2017 
cohort 
1:150, 
cohort 
2:260 
Dement
ia vs 
MCI 
S-MoCA DSM IV <12/16 
cohort 
1:94%, 
cohort 2: 
98% 
cohort 1: 
25%, 
cohort 2: 
7% 
Panenkova 
2016 540 CI Abbreviated MoCA MoCA <4/8 89% 64% 
Roalf 2017 1850 
All 
cause 
dement
ia vs 
HC 
s-MoCA DSM IV <12/16 62% 86% 
Wittich 
2010 277 AD MoCA-Blind NPB 
Absolute  
≤17/22 87%  98% 
Xu 2016 405 
CIND, 
dement
ia 
NINDS-CSN 5 min protocol MDT Consensus 
Not 
reported Not reported 
Not 
reported 
 
aData obtained through contacting authors 
bData obtained from ROC curve 
Where multiple cut-offs were presented, we chose the optimal cut-off as specified by the author. Where various 
reference standards were described, we describe the comparator closest to clinical diagnosis of dementia. Full 
Characteristics of included studies table is available in Supplementary Table 1.  
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Abbreviations: CA, conference abstract; CDR, Clinical Dementia Rating; CI, Cognitive Impairment; CIND, 
Cognitive Impairment, no dementia; DSM, Diagnostic and Statistical Manual; HC, Healthy Control; MCI, Mild 
Cognitive Impairment; MDT, Multidisciplinary Team Assessment; NPB, Neuropsychological battery; NINDS-
CSN, National Institute of Neurological Disorders and Stroke and the Canadian Stroke Network 
Table 3. Rank correlation between individual domains of the Montreal Cognitive Assessment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grey cells are the stroke data and white cells are the memory clinic data. Those items where correlation was not significant at <0.0001 are in bold type
 TRAILS CUBE CLOCK  NAMING  DIGITS LETTERS SUBTRACTION  REPEAT FLUENCY ABSTRACTION RECALL ORIENTATION 
TRAILS 1 0.48 0.50 0.39 0.38 0.38 0.46 0.17 0.38 0.30 0.38 0..40 
CUBE 0.40 1 0.46 0.31 0.30 0.28 0.35 0.14 0.29 0.35 0.36 0.31 
CLOCK 0.38 0.38 1 0.53 0.46 0.44 0.54 0.27 0.43 0.31 0.45 0.51 
NAMING 0.23 0.24 0.23 1 0.39 0.40 0.41 0.20 0.39 0.28 0.37 0.42 
DIGITS 0.27 0.17 0.19 0.23 1 0.33 0.49 0.27 0.31 0.26 0.36 0.35 
LETTERS 0.24 0.16 0.23 0.15 0.30 1 0.42 0.21 0.36 0.28 0.34 0.42 
SUBTRACTION 0.37 0.33 0.40 0.38 0.31 0.27 1 0.22 0.44 0.30 0.38 0.51 
REPEAT 0.27 0.15 0.34 0.22 0.36 0.23 0.26 1 0.18 0.11 0.21 0.20 
FLUENCY 0.30 0.24 0.21 0.14 0.33 0.23 0.26 0.26 1 0.25 0.44 0.20 
ABSTRACTION 0.29 0.32 0.28 0.29 0.23 0.21 0.32 0.33 0.19 1 0.31 0.27 
RECALL 0.32 0.30 0.28 0.19 0.24 0.16 0.26 0.23 0.20 0.36 1 0.41 
ORIENTATION 0.38 0.31 0.46 0.23 0.26 0.19 0.39 0.29 0.26 0.31 0.45 1 
Figure 1. PRISMA flow diagram  
 
Figure 2. Correlation and test accuracy of short forms of the Montreal Cognitive 
Assessment  
 
Supplementary Appendix 1. Virtual International Stroke Trial Archive (VISTA) - 
Cognition Steering Committee 
 
Supplementary Methods 1. Search syntax used across electronic databases 
 
Supplementary Table 1. Characteristics of studies included in systematic review 
 
Supplementary Table 2. Risk of bias and applicability concerns for papers describing 
short form Montreal Cognitive Assessment using the QUADAS-2 tool 
 
Supplementary Table 3. Quality of reporting for papers describing short form Montreal 
Cognitive Assessment using the STARDdem tool  
 
Supplementary Table 4. Correlation of each item with total Montreal Cognitive 
Assessment (MoCA) and internal consistency (Cronbach’s alpha) if that item removed 
(Data from independent stroke and memory clinic data-sets) 
 
Supplementary Table 5. Factor pattern for all items of Montreal Cognitive Assessment 
(MoCA) 
 
